Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intuvax in Progressing GIST
NCT02686944Phase 1Completed
- Sponsor
- Mendus
- Start
- Jun 2016
- Primary completion
- May 2019
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ilixadencel in gastrointestinal stromal tumor (GIST), sponsored by Mendus. Primary endpoints: Changes in vital signs up to 12 months, Changes in lab parameters up to 12 months and 1 more. Started Jun 2016; status: completed.
02
Drugs
ilixadencel
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT02686944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686944.